Search - tctmd.com

Displaying 481 - 500 of 818

Sort: Relevancy | Date

REVASCTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

News Conference News TCT 2017

REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

Todd Neale

October 31, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

Presentation TCT 2017

TCT 51: Impact of Anticoagulation Therapy on Valve Hemodynamics and Clinical Outcomes After Bioprosthetic Aortic Valve Replacement: A Pooled Analysis of the PARTNER2 Trials

Presenter: Peter C. Block, Lars Sondergaard, Tarun Chakravarty, MD

October 31, 2017

Presentation TCT 2017

ABSORB 3-Year Meta-analysis: 3-Year Outcomes of a Bioresorbable Scaffold Compared to a Metallic DES From an Individual Patient Data Meta-analysis of Four Randomized Trials

Presenter: David P. Faxon, Joseph A. Hill, Ziad A. Ali

October 31, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

Presentation TCT 2017

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Gregg W. Stone

October 31, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

Shelley Wood

October 31, 2017

Presentation TCT 2017

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Stephen G. Ellis

October 31, 2017

Presentation TCT 2017

Featured Lecture: The NIH Mission to Enhance DIVERSITY in Clinical Trials, Education, and the Workforce

Presenter: Roxana Mehran, George A. Mensah

October 31, 2017

Presentation TCT 2017

Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE

Presenter: Robert A. Harrington, Sanjay Kaul, Schuyler Jones

October 30, 2017

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

News Conference News TCT 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Todd Neale

October 30, 2017

Presentation TCT 2017

Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations)

Presenter: Robert A. Harrington, Sanjay Kaul, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

Amulet: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy, Fabian Nietlispach

October 30, 2017

Presentation TCT 2017

Clinical Trials Using RAPID: Some POC Thoughts

Presenter: Schuyler Jones, Hiroyoshi Yokoi, Theodore Heise

October 30, 2017

Presentation TCT 2017

WATCHMAN: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy

October 30, 2017

Presentation TCT 2017

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, C. Michael Gibson

October 30, 2017

Presentation TCT 2017

Perspectives on Current Trials in Renal Denervation: Evolution of Design, Endpoints, and Objectives

Presenter: Michael Böhm, Thomas F. Luscher, Felix Mahfoud

October 30, 2017

Presentation TCT 2017

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, Kurt Huber

October 30, 2017

Presentation TCT 2017

Diversity in Clinical Trials (Lessons Learned, Future Directions): Inclusion of Women

Presenter: Wayne B. Batchelor, George A. Mensah, Roxana Mehran

October 30, 2017

Advertisement

REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

Long-term Absorb BVS Data Continue to Disappoint

TCT 51: Impact of Anticoagulation Therapy on Valve Hemodynamics and Clinical Outcomes After Bioprosthetic Aortic Valve Replacement: A Pooled Analysis of the PARTNER2 Trials

ABSORB 3-Year Meta-analysis: 3-Year Outcomes of a Bioresorbable Scaffold Compared to a Metallic DES From an Individual Patient Data Meta-analysis of Four Randomized Trials

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Live From Denver: TCT 2017, Day Two

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Featured Lecture: The NIH Mission to Enhance DIVERSITY in Clinical Trials, Education, and the Workforce

Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations)

Amulet: Data Synthesis and Ongoing Trials

Clinical Trials Using RAPID: Some POC Thoughts

WATCHMAN: Data Synthesis and Ongoing Trials

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Perspectives on Current Trials in Renal Denervation: Evolution of Design, Endpoints, and Objectives

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Diversity in Clinical Trials (Lessons Learned, Future Directions): Inclusion of Women

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content